The risk of product recalls across five key industries remains prevalent in the U.S. according to data from Sedgwick’s latest Recall Index report. Despite recall activity falling less than one percent in Q2 2023 compared to the previous quarter, at o…
European product recalls increased 6.1% in the first quarter of 2023, according to Sedgwick brand protection’s latest European recall index report. In total, the European automotive, consumer product, food and beverage, pharmaceutical, and medical de…
According to our latest European product recall index report, the overall number of recall events in Europe fell 8.8% in the third quarter, compared to Q2. The pharmaceutical sector experienced the greatest decline, registering 25.0% fewer events. Th…
Reports indicate that the European Commission’s proposed overhaul of the EU’s general legislation on medicines for human use was rejected by the Regulatory Scrutiny Board, sending it back to the Commission for revision. The Commission was originally…
The total number of U.S. products recalled this year has now topped 1 billion, according to our latest U.S. product Recall Index. More than 1 billion units have been recalled only twice before in history, in 2018 and 2021. However, it took a full yea…
While regulators and business leaders enter the third calendar year of COVID-19, some new challenges are emerging atop the lingering supply chain and service issues brought on by the pandemic. The Biden administration continues to push for more consu…
While there’s light at the end of the COVID-19 tunnel and consumers anticipate a return to normal, ‘business-as-usual’ is still a long way off, as reported in our 2021 Recall Index report. Essential reading for manufacturers and retailers seeking i…
As the post-COVID-19 world begins to reopen, we’re starting to find our way back to normalcy. But regardless of how quickly the entire country returns to "business as usual", risks to brand reputations are likely to increase as regulators resume work…
It’s been over two years since carcinogenic nitrosamines were discovered in some widely used drugs. The discovery occurred in 2018 when the contaminant was found in active pharmaceutical ingredients in Valsartan, a blood pressure medication. Since th…
COVID-19 may have stalled huge sectors of the global economy, but regulatory oversight in the U.S. remains vigilant and may even be picking up its pace as we move through the third quarter. In fact, medical device recalls in the second quarter reach…
Until a few months ago, few if any senior executives had personal experience managing a company during a pandemic. Making matters more difficult, there’s really no recent history to consult to determine what perils lie ahead, which processes work and…
As the number of COVID-19 cases continues to increase worldwide, numerous questions and a tremendous amount of misinformation cloud the issue. Many remain confused about how the virus is transmitted, how dangerous it is, and what treatments for it ma…
While U.S. product recalls were relatively flat from the second to the third quarter, expect an upsurge in the weeks and months to come as regulators – under growing pressure from Congress and consumer groups – turn their attention to currently unreg…
When a consumer’s smartphone spontaneously combusts, the word-of-mouth news spreads to millions within days if not hours. If a certain blood pressure medicine is contaminated with a potentially cancer-causing agent, it could take months before routin…